

OxySure Therapeutics (OXYS) to Present at the 2nd Annual Innovations Investor Conference in Miami

Unique Panel Discussion on "How Sports Can Enhance Your Business"

Frisco, Texas, February 2, 2016 – OxySure Therapeutics, Inc. (OTCQB: OXYS) ("OxySure," or the "Company"), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen products with its "oxygen from powder" technology and other innovative emergency medical solutions today announced that the Company will be presenting at the second Annual Innovations Investor Conference in Miami, FL on Monday, February 22, 2016 at the Ritz-Carlton South Beach, presented by SeeThruEquity and The Brewer Group.

This conference represents an opportunity for small cap, middle market, and emerging public and private companies to showcase their products, services, and programs while facilitating opportunities to collaborate and exchange ideas with potential strategic partners, presentations on innovative technologies and products, access to private and institutional investors, and networking receptions. The event will provide an intimate, exclusive platform to bring experts, investors, and companies together to help identify strategic partnerships. The 2016 conference will feature 30 minute presentations and 1x1 meetings scheduled with hundreds of investors.

"We look forward to presenting at this dynamic conference," stated Julian T. Ross, CEO of OxySure, "and we are especially excited about this year's unique panel discussion on "How Sports Can Enhance Your Business," sponsored by Brewer Sports International, which brings together professional athletes and company executives to discuss the various ways that sports can impact and enhance small growth companies."

According to The Brewer Group nearly 50 professional athletes are expected to be in attendance for the event. The OxySure Model 615 portable oxygen device has a strong presence and growing usage in athletics and sports, especially in K-12 as well as collegiate sports. OxySure was recently highlighted as one of three stocks that tackle concussion issues in professional and non-professional athletes. A copy of the article can be found here: http://www.biotechstocktrader.com/3-stocks-tackling-concussion-issues-in-pro-athletes/

The Company further noted that the OxySure Model 615 meets the protocol for asthma emergencies and for exertional sickling, recommended by the National Athletic Trainers' Association (NATA). The NATA treatment protocols recommend that "supplemental oxygen should be offered to improve the athlete's available oxygenation during asthma attacks." The protocols further stipulate that "for breathing distress, the sports medicine team should provide supplemental oxygen to help maintain blood oxygen saturation above 92%." Similarly, the protocols recommend that athletes with known sickle cell trait (SCT) should "...have supplemental oxygen available for training or competition..."

The OxySure Model 615 was also used successfully a total of 18 times during the Special Olympics World Games in July 2015 in Los Angeles, where the Company provided support to the medical operations of the Games to help cover medical emergencies during the nine days of competition, involving 7,000 athletes and 3,000 coaches from 177 countries, plus an estimated 500,000 spectators. OxySure served as the supplier of emergency oxygen, Automated External Defibrillators (AEDs), oxygen pulse oximeters and other medical emergency equipment and services to the Games. A copy of the press release can be found here: http://www.oxysure.com/2015.08.06_special_olympics_18_saves.pdf

About OxySure Therapeutics, Inc.

OxySure Therapeutics, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com

Contact:

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com 800-733-2447, ext. 107 www.redchip.com/

Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management's control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Therapeutics, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Therapeutics, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Therapeutics, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2014.